CA1190148A - Interferon-containing compositions - Google Patents
Interferon-containing compositionsInfo
- Publication number
- CA1190148A CA1190148A CA000413238A CA413238A CA1190148A CA 1190148 A CA1190148 A CA 1190148A CA 000413238 A CA000413238 A CA 000413238A CA 413238 A CA413238 A CA 413238A CA 1190148 A CA1190148 A CA 1190148A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- surface active
- active agent
- interferon
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
A composition useful for treating herpes simplex viral infections in humans comprises about 102 to 108 I.U. of human interferon, about 0.1% to about 20% by weight of an antiviral surface active agent and a physiologically acceptable carrier. Preferably, the interferon-containing composition comprises about 104 to 106 I.U. of human leukocyte interferon, about 1% to 5% by weight of a non- ionic surface active agent having at least one ether amide linkage, and a physiologically acceptable carrier. These interferon-containing compositions are useful for treating herpes simplex viral infections in humans by topically administering an effective amount of the above-identified interferon-containing antiherpetic composition to the affected area. Preferably, an effec-tive amount of the interferon-containing antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication.
These interferon-containing compositions are usefully applied to the genital area of a human and, when so applied, would appear to be useful as a prophylactic for or in the treatment of in situ cervical carcinoma, since there is some belief that herpes simplex infection might be a co-carcinogen or a background etiological agent which might lead to in situ cervical carcinoma.
A special aspect of the use of these interferon-containing compositions is the use of these compositions in the treatment of skin malignancies, pre-malignant skin lesions and skin diseases, such as herpes zoster and psoriasis. These interferon compositions are also useful in the treatment of basal cell carcinoma, squamous cell carcinoma or squamous carcinoma, actinic keratosis and leukoplakia.
A composition useful for treating herpes simplex viral infections in humans comprises about 102 to 108 I.U. of human interferon, about 0.1% to about 20% by weight of an antiviral surface active agent and a physiologically acceptable carrier. Preferably, the interferon-containing composition comprises about 104 to 106 I.U. of human leukocyte interferon, about 1% to 5% by weight of a non- ionic surface active agent having at least one ether amide linkage, and a physiologically acceptable carrier. These interferon-containing compositions are useful for treating herpes simplex viral infections in humans by topically administering an effective amount of the above-identified interferon-containing antiherpetic composition to the affected area. Preferably, an effec-tive amount of the interferon-containing antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication.
These interferon-containing compositions are usefully applied to the genital area of a human and, when so applied, would appear to be useful as a prophylactic for or in the treatment of in situ cervical carcinoma, since there is some belief that herpes simplex infection might be a co-carcinogen or a background etiological agent which might lead to in situ cervical carcinoma.
A special aspect of the use of these interferon-containing compositions is the use of these compositions in the treatment of skin malignancies, pre-malignant skin lesions and skin diseases, such as herpes zoster and psoriasis. These interferon compositions are also useful in the treatment of basal cell carcinoma, squamous cell carcinoma or squamous carcinoma, actinic keratosis and leukoplakia.
Description
3`1~ 3 INTERFERON-CONTAINING COMPOSITIONS AND THE
USE OF THESE COMPOSITIONS IN THE TREATMENT
OF HERPETIC INFECTIONS, PRE-~ALIGNANT SXIN
LESIONS, SKIN MALIGNANCIES AND PSORIASIS
BACXGROUND OF THE INVENTION
This invention relates to a composition and a method for treating herpes simplex infections in humans. More particularly, this invention relates to a pharmaceutical composition containing interferon and an antiviral surface active agent, and to a method for treating ~erpes simplex infectlons in humans by topically administering said pharmaceutical composition to the affec~ed area.
Infections by herpes simplex virus are extremely common in humans. The virus is transmitted by direct contact with infected individuals and it is estimated that more than half the human population has been infected by herpes simplex virus at one time or another.
Once an individual is infected, the virus manifPsts itself as sores or lesions on various parts of the body. Herpes labialis is the most clinical form of herpes simplex virus infection. The symptoms include inflammation of the mouth and gums as well as mouth eruptions (cold sores)~ The cold sores are often painful and unsightly.
In another common clinical form, herpes genitalis, eruptions occur in the genital area. Herpes genitalis is a serious problem. It often causes severe psycho-logical and social problems in afected individuals.
It can be ~atal to patients with deficient immune systems. In addition, it presents the risk of infections to the newborns of infected mothers, often a fatal disease to the infant.
~3¢3~
Herpes simplex virus may also infect the eye producing acute kera~itls, and may infect the central nervous system resulting in severe encephalitis.
Although it was once thought that there was only one type of herpes simplex virus, it is now known that there are two major types of the virus. Herpes simplex virus type 1 (hereinafter HSV-l) is usually associated with herpes labialis. Herpes simplex virus type 2 (hereinafter HSV-2) is usually associated with herpes genitalis.
However, HSV-l has been isolated in some instances from genital lesions, while HSV-2 has been isolated from lesions on parts of the body other than the genitals.
In some reports, HSV-l has been linked to lip cancer while HSV-2 has been linked to cervical and vulvar cancer.
Following the initial infection with either HSV-l or HSV-2 lesions may or may not appear. However, the virus does not die but continues to reside in a latent form in the nerve ganglia. Recurrent attacks may occur throughout life in response to non-specific stimuli, for example, in response to changes in body temperature, stress, ultra-violet radiation, hormonal changes, etc. It is believed by some ~hat recurrent attacks occur when the host's immune system is suppressed. At that time, virus latent in the ganglia travels along the nerve cells without damaging them until it emerges from ~he ends of the nerves. As it emerges, the virus infects the adjacent cells and begins to multiply.
Viral multiplication takes place in two stages eventually resulting in a lesion. In the first stage, known as the prodromal stage, the number of viral particles increases until a first maximum is reached. During this stage, the ~ ~3~
~ 3--patient may feel a tingling sensation at the site o viral multiplication. The nubmer of viral particles decreases thereafter. ~bout two to three days after the prodromal stage, the viral particles undergo a second stage of multiplication. In the second stage, number of viral particles increases until a second maximum, much larger than the first maximum, is reached.
The second stage of multiplication causes the death of many cells and results in a lesion. Usually, the lesion heals within 10 to 14 days but in some cases the lesion can last much longer.
Many claims have been made for effective antiherpetic compositions. Undoubtedly, the benefits demonstrated by many of these compositions in in vivo tests may be attributed to a placebo effect. This effect may be as high as 50~ for herpes simplex viral infections. One group of chemical agents which proved effective against herpes simplex virus in in vitro tests is the group comprising lipid-dissolving anionic and cationic surface active agents. The effectiveness of these ayents has been attributed to their ability to dissolve the lipid-; containing membrane which surrounds the nucleocapsid of both HSV-l and HSV-2.
More recently, it has been discovered by one of the inventors herein along with others that nonionic surface active agents are also effective in reducing the infectiv-ity of herpes simplex virus. For example, in Asculai, S.S., et al, Antimicrobial Agents and Chemotherapy, 13, 686 (1978), it is reported that certain nonionic surface active agents rapidly reduced the infectivity of HSV-l and HSV-2 in vitro. The nonionic surface active agents which inactivated the infectivity of herpes simplex virus were those possessing ether or amide linkages between the hydrophilic and the hydrophobic portions of the molecule.
See also U.S. 4,020,1~3 (Asculai et al) and U.S. 4,139,630 ~Asculai et al). The therapeutic effect of these nonionic s~rfactants was also a~tributed to their abili~y to dissolve the lipid~containing envelope of herpes simplex virus. The nonionic surfactants were also r~ported to destroy partially the nucleocapsid of the virus. The nonionic surfactants find use as spermicides in vaginal contraceptives. Contraceptive formulations containing nonionic surfactants were also demonstrated to be effective against herpes simplèx virus.
The treatment of herpes simplex virus infections by topical administration of surface active agents,whether anionic, cationic, or nonionic, does not produce entirely 15 satisfactory results. The most beneficial results are obtained when the surfactant is applied during the pro-dromal sta~e before the lesion appears. However, it is often difficult to tell when the virus is in the prodromal stage of multiplication. Furthermore, the surface active agent is applied to the uppermost layer of infected cells.
Because of the dilution efect, the cells below the uppermost layer do not receive sufficient amounts of the surface active agent to destroy the viral particles.
Thus, no protection is provided for cells below the surface layer and herpes simplex virus continues to multiply in those cells below the surface layer.
Additionally, treatment with the antiviral surface active agent does not appear to reduce the requency of recurrent attac~s. It is believed, however, that recurrent attacks might be prevented if suf f icient numbers of the multiplying viral particles are destroyed.
It would thus be desirable to provide a pharmaceutical composition which reduces the load of herpes simplex virus so that latency is not reestablished.
q;-~13 It would also be desirable to provide a pharmaceutical composition which prevents spread of the virus to cells below the surace layer.
Human interferon is known to protect cells against viral infections. Human interferon is produced by cells in reaction to the presence of specific inducers, such as viruses. It may be produced ln vivo by the cells of living organisms, or it may be produced in vitro by cell cultures in response to the presence of the inducer. There are now known to be three main varieties cf human interferon: leukocyte or ~ , fibro-blast or ~, and immune or y interferon. There are also known to be several sub- varieties of human leukocyte and fibroblast interferon~
Human interferon is relatively nontoxic and nonantigenic in humans. It is also extremely effective against a broad spectrum of viruses, including herpes simplex virus, even at very lo~- concentrations Until the present, treatment of herpetic lesions with human interferon has proceeded along two main courses: a) medi-cinal induction of endogenic interferon in the patent, and b) administration of exogenic interferon to the patient.
For example, U.S. 4,053,582 (Stickl) discloses a method for treating herpes simplex infections in humans by administering attenuated fowl pox virus to the patient.
The attenuated virus induces the patient to produce his own interferon. The herpetic lesions heal within a short time after induction.
U.S. 4,061,538 (Dorner et al) and 4,184,917 (Dorner et al) disclose a method of treating herpes simplex viral infections by administering structurally modified 3~
interferons to the patient. In these patents, the modified interferons are administered systemisally to the patient.
Several published reports also disclose the treatment of herpetic eye infections by topical administration of human interferon. For example, see D. Naumann-Haefelin et al in Infection and Immunity, 17, 468 (1977) and B. R. Jones et al in Lancet ii, 128 (1976).
None of these disclosures suggests the treatment of herpes labialis and herpes genitalis in humans by administering topically an interferon-containing pharmaceutical composition. Moreover~ none of these disclosures suggests the treatment of herpes simplex viral infections by administering topically a combina-tion of human interferon and an antiviral surface active agent.
This invention also relates to a method for treatment of skin malignancies and pre-malignant skin lesions, including squamous cell carcinoma, basal cell carcinoma, actinic keratosis, and leukoplakia. This invention also relates to a method for treatment of psoriasis and herpes zoster.
3..3 ~3~
Basal cell carcinomas, which ma~f appear as small, shiny, firm nodules or ulcerated crusted lesions on the skin, are generall~ treated by electrodesicca-tion and curettage, surgical excision or X-ray therapy~ In about 5% of cases ~ recurrences occur.
Such recurrences are treated typically with further excision or Moh's chemosurgery, i.e., microscopically controlled excision after chemical fixation of the tissue.
10 - .
Squamous cell carcinoma arises from the malpighian cells of the epithelium. The tumor generally begins as a small red papule or plaque with a scaly or crusted surface. Subseque~tly, it becomes nodular.
Eventually, the lesion ulcerates and invades the underlying tissue. As with basal cell carcinoma, squamous cell carcinoma is treated with electro-desiccation and curettage, surgical excision or X-ray therapy.
Precancerous keratotic lesions, actinic keratoses, are the frequent consequence of many years of over-exposure to sunlight. The keratoses are usually hard, and gray to dark in color. Such lesions are ~5 generally treated by topical application of fluoro-uracil (5-fluorouxacil). However, if the lesions become malignant, topical application of fluoroura-cil is not recomme~ded as the rate of recurrence is unacceptably high with such therapy.
3~
Leukoplakia~ hyperkerati.nizatlon of th~ oral mucosa, is generally believed to result from several factors, local or systemic, ac~ing independently or in com-~ination, such as: tobacco, alcohol, chronic irrita-tion from such causes as cheek biting, ill-fitting dentures, shaxp, broken or worn--down teeth or spicy foods, syphillis, vitamin deficiency, hormonal changes and C~ndida a~bicans. Leukoplakia lesions vary from a small, well-localized white patch to a`diffuse area involving much of the oral ~ucosa, and from a smooth, flat, or slightly elevated, translucent white plaque to a thic~, fissured papillomatous lesion that is firm to palpation. Treatment of leukoplakia generally comprises initial removal or elimination of any recogniz-able irritating factors, such as tobacco or faultyrestoration or pros~hetic devices, to chemical irri-tants, and total excision or cauterization of the localized lesions. Large lesions may be removed by a series of "stripping" operations. The patient should additionally be re-examined periodically and any lesions subsequently located biopsied because of the pre-cancerous nature of the disease. Additionally, leu~oplakia may be involved in lesions of -the vulva and anus~ When involved wlth the vulva, leukoplakia is treated by total vulvectomy.
Psoriasis is characterized by skin lesions which are sharply demarcated, usually non-pruritic, erythematous papules or plaques covered with overlapping, silvery 3Q or slightly opalescent, shiny scales. The typical course of psoriasis is chronic remission and recur-rence, which vary in frequency and duration. Psoria-sis varies in severity from one or two lesions to a widespread dermatosis, to psoriatic arthritis or exfoliation. Treatment depends upon the extent and :3.'~ 3~
severity of the involvement. The simplest form of trea~ment, topical application of lubricants, kerato-lytics and corticosteroids, is initially employed.
Systemic antimetabolltes should be used only in severe 5 skin or joint involvemen-t because of their potential adverse effects. Exposure to ultraviolet light has bPen found helpful in the treatment of psoriasis.
~lethotrexate taken orally is generaLly an effective treatment in severe disabling psoriasis which has not responded to topical therapy. However, because of the toxicity of met~otrexate, hematological, renal and hepat-ic functions of the patient must be carefully monitored.
Herpes zoster is a virus-related, acute CNS infection involving primarily the dorsal root ganglia, and characterized by vesicular eruption and neuralgic pain in the cutaneous area supplied by peripheral sensory nerves arising in the affected root ganglia.
Herpes zoster may be activated by local lesions or bY
systemic disease, among other reasons. Prodromal symptoms of chills and fever, malaise and ~I dis-turbances may be present for three or four days be-fore the distinctive features of the disease develop.
On about the fourth or fifth day, characteristic crops of vesicles on an erythematous base appear, following the cutaneous distribution of one or more posterior root ganglia. There is no specific treat-ment for herpes zoster. ~arly systemic application of a corticosteroid, however, generally relieves pain.
It would thus be desirable to provide a method for treatment of malignant and pre-malignant skin lesions, which comprises topical administration of an effective agent.
It would also be desirable -to provide an effective method for treatment of malignant and pre-malignant skin lesions which employes topical application of a non-toxic agent.
It would also be desirable to provide an effective method for treatment of psoriasis comprising topical administration of a non-toxic and relatively non-antigenic agent.
It would further be desirable to provide a method for treatment of herpes zoster comprising topical adminis-tration of an effective, therapeutic agent.
Human interferon is known to protect cells against viral infection. Human interferon is produced by cells in reaction to the presence of specific inducers, ,uch as viruses. It may be produced in vivo by the cells of living organisms, or it may be produced in vitro by cell cultures in response to the presence of the inducer. There are now known to be three main varieties of human interferon: leukocy~e (~3, fi~ro-blast (~) and immune (y). Additionally, there are also known to be several subvarie-ties of human leuko-cyte (a) and fibroblast (~) interferon.
Human interferon is nontoxic and relatively nonanti-genic in humans. It is an effective agent against a broad spectrum of viruses, including herpes simplex virus. For example, U.S. Pat. No. 4,061,538 (Dorner et al.) and U.S. Pat. No. 4,184,917 (Dorner et al.) disclose a method of treating herpes simplex viral infections by ~m; ni stering structurally modified interferons to the patient. The method of adminis-tration disclosed in the Dorner patents is systemic.
~ 3~
Several published reports also disclose treatment of herpetic eye infections by ~opical administra~ion of human interferon~ For example, see D. Na~nann-Haefelin et al~ in Infection ~nd Immunity, 17:458 (1977) and B. R. Jones et al. in La~cet i~ :128 (1976).
It has also been recently discovered that nonionic surace active agents (such as are employed as spermicides in ~aginal contraceptives) are effective in treatment of viral skin diseases. For example, in Asculai, S.S. et al; An~imicrob~a~ Agents ~d Chemother~py, 13:686 ~1978), it is reported that cer-tain nonionic surface active agents rapidly reduce the infectivity of herpes simplex ~iruses (HSV-1 and lS HSV-2) in vitro~ The nonionic surface active agents which inactivated the infPctivity of the viruses were those possessing e-ther or amide linkages between the hydrophilic and the hydrophobic portions of the molecule. See also U.5. Pat. No. 4,020,183 (Asculai et al.) and U.5. Pat. No. 4,139,630 (Asculai et al.) The therapeutic effect of such nonionic surfactants was attributed in part to their potential to dissolve the lipid-conta;ni ng envelope of the virus. The non-ionic surfactants were also reported to partially dest~oy the nucleocapsid of the virus.
B
Accordingly, it is an object of the ~resent inv~ntion to provide novel pharmaceutical compositions containing human interferon and an antiviral surface active agent.
It is also an object of the present invention to provide a method for treating lesions due to herpes simplex virus by topically administering the aforesaid pharmaceutical compositions.
I~ is a further object of the present invention to provide compositions for treating herpetic lesions which not only heal the lesions but may also reduce recurrent attacks.
I-t is another object of the present invention to provide a method for treatment of malignant and pre-malignant skin lesions, herpes zoster and psoriasis.
It is also an object of the present invention to provide a method of treatment of skin malignancies and pre-malignant lesions, herpes zoster and psoriasis which comprises topical treatment of the affected skin area with a pharmaceutical composition.
It is another object of this invention to provide a method for treatment of malignant and pre-malignant skin lesions by topical administration of a nontoxic pharmaceutical composition.
It is a further object of this invention to provide a method for treatment of skin lesions produced by squamous cell carcinoma, basal cell carcinoma, actinic keratosis, leukoplakia, psoriasis and herpes zoster which comprises administration of a relatively nonantigenic pharma-ceutical preparation.
B
13~How these and other objects of this invention are achieved will become apparent in light of the accom-panying disclosure and claims.
5 SUM~l~Y OF THE INVENTION
A composltion fox treating herpes simplex viral infec-tions comprises about 102 to 103 I.U. of human inter-feron, about 0.1% to 20% hy weigh~ of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, a composition for treating herpes simplex viral infections comprises about 104 to 106 I.U. human leukocyte interferon, about 1% to 5% by weight of a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carxier. Amethod for treating herpes simplex viral infections in humans comprises topically administer-ing to the affected area an effective amount of said compositions. Most preferably, a method for treating herpes simplex viral infections in humans comprises topically administering to the affected area an effective amount of said compositions during the pro-dromal stage of viral multiplication.
A method for treating skin malignancies, pre-malignant skin lesions, and lesions associated with psoriasis and herpes zoster comprises topically administering to the affected skln area an effective amount of a compo-sition comprising about 102-lO~ IU of human interferon, about 0.1% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier-The topical administration could be achieved by direc~
application of the pharmaceutical product with or with-out an occlusive dressin~. The method of treatment for malignant and pre-malignant skin lesions would preferably involve daily application of a composition containing human interferon and an antiviral surface~
active agen~ with an occlusive dressing. Such treatment o~ the lesions would pxeferably continue for ten days, at which point evaluation of the trea-tment would be madQ.
DETAILED DESCRIPTION OF THE INVENTION
The novel pharmaceutical compositions of the present invention contain effective amounts of human interferon, an antiviral surface active agent, and a physiologically acceptable carrier. The pharmaceutical compositions may contain any of the known varieties or sub-varieties of human interferon~ Thus, the composition may con~aining human leukocyte, fibroblast, or immune interferon. Additionally, the interferon may suitably be prepared by "classical" culture methods or by recom-binant DNA methods. An effective dosage of human inter-feron for treating herpetic lesions in accordance with the practices of the present invention is about 10Z to loB, preferably about 104 to 106, I.U.
The antiviral surface active agent may be anionic, cation-ic, or, preferably, nonionic. Antiviral surface active agents are known in the art. These surfactants dramati-cally reduce the infectivity of HSV-l and HSV-2 by damag-ing or destroying the lipid envelope of the virus.
Suitable anionic surfactants include sodium alkylsulfon-ates and sodium alkylbenzenesulfonates. Suitable cationic surfactants include quaternary ammonium detergents, such as cetyl pyridinium chloride, and benz-alkonium chlorides.
Nonionic surface active agents are preferred in the pharmaceutical preparations of of the present invention.
~15-- , In contrast to cationic, anionic, and ampholytic surface active agents, the nonionics containing no ionizable groups and have no surface charge. They depend upon their entire molecule for surface activity. Almost any hydrophobic compound which has in its structure a carboxy, hydroxy, amido or amino group with a free hydrogen attached to the nitrogen, can be reacted with ethylene oxide to form a nonionic surfacant. At least three groups of nonionic surfactants are recognized:
1~ a) those having an ether linkage between the hydrophilic and hydrophobic portions of the molecule, b) those having an ester or ether-ester linkage, and c~ those having an amide linkage. Nonionic surfactants having at least one ether or amide linkage are preferred for pur-poses of the present invention. Examples of preferrednonionic surfactants include the following: nonyl-phenoxy-polyethoxy ethanol (available under the trade name Nonoxynol-9), p-diisobutylphenoxypolyethoxy ethanol (available under the trade name Triton X-100), polyoxyethylene (10) oleyl ether (available under the trade name Brij-97), and onyx-ol (available under the tradename Onyx-ol 345).
An effective dosage of an antiviral surface active agent for purposes of the present inventions comprises about 0.1% to 20% by weight of the pharmaceutical composition~ The preferred range is about l~ to 5% by weight.
The balance of the pharmaceutical compositions comprises an inert, physiologically acceptable carrier. The carrier should not react with the active ingredients and not reduce their effectiveness. Suitable physiologically acceptable carriers include water t ethanol, polyethylene glycol, mineral oil, petrolatum, propylene glycol, and ~ 16-the like. The pharmaceutical compositions are prefer ably administered in lotion, cream, oil, or emulsion fo.rmulations.
The following are examples of suitable formulations containing a nonionic surfactant and human interferon:
Pharmaceutical Lotion propylene glyool 24.75 ml.
~riethanolamine l.00 ml.
water 7.00 ml.
oleic acid 1.50 gm.
polyethylene glycol monostearate lO.50 gm.
silicon fluids lO.. 00 ml.
carbopol-934 (2% mucilage)50.00 ml.
human leukocyte in~erferon~0-lO8 I
Pharmaceu~ical Cream ~
white petrola~um 41.00 gm microcrystalline wax 3.00 gm flUid lanolin lO.00 gm 50~bitan monooleate 4.75 gm p~lysorba~e-80 0.25 gm purified water - 41.00 ~
huma~ leukocyte in~erferonlOÇ-lO- I.U.
Pharmaceu~ical Cream B
~permaCQti 7~5~
white wax 12.0%
mineral oil 56 . 096 sodium bora~e O. 5~
sor~itan monooleate 5. 0%
water 19 Og~
hu~narl leukocyte interferon10 ~-lQ7 I .U .
.3~3~ 3 Topical administration oE pharmaceutical compositions of the present invention may be effec~ed by applying a small amount (e.g., about 1 ml) of the compositions directly to and in areas adjacent to the site of the lesions with a cotton swab, soft brush, sponge or the like. Any quantity sufficient to cover the area of the lesions is effective. 'rreatment with the pharmaceutical compositions herein disclosed should be fre~uent, for example, every 2-4 hours, for about 3-4 days. Preferably, the pharmaceutical compositions are applied during an early stage o viral multiplication. For example, the compositions may be applied during the prodromal stage in the areas wherP a tingling sensation is felt. When the compositions are applied to lesions, the pain is substantially reduced within 1 hour in almost all cases.
The lesions are noticeably improved within 4 to 12 hours, and are completely healed within 4 to 5 days with little or no scarring. When the compositions are applied during the prodromal stage, the tingling sensation usually disappears within the hour and the compositions provide a prophylaxis against emergence of the lesions. In some cases, no lesion appears at all; in other cases a small blister appears which disappears within 2-3 days.
Additionally, treatment of herpes simplex virus infec-tions in accordance with the present invention appears toreduce the frequency of recurrent attac~s and in some cases apparently eliminates the virus altogether. No contraindications have been found.
The pharmaceutical compositions of the present invention also display antimicrobial activity as well as antiviral activity. For example, they are effective in treating warts as well as bacterial infections. As used herein herein, the term antimicrobial activity refers to activity against microorganisms other than viruses such as bacteria and fungi.
In addition to direct application, the pharmaceutical compsoitions may be administered topically by various other methods. For example, the compositions may be delivered to the affected region in microencapsulated form. They may also be deliv red in a foam, by spray, tampon, vaginal suppository, etc.
Although it is not completely understood, it i5 believed that the pharmaceutical compositions herein disclosed operate in the following manner. The antiviral surface active agent dissolves the lipid-containing envelopes of herpes simplex virus thereby destroying its infectiv-ity. The interferon aids the cells in preventing viral replication. In addition, because very few interferon molecules are needed to protect a cell, the interferon prevents the spread of the virus to cells below the uppermost layer. Thus, the combination of a surface active agent, such as a nonionic surface active agent, and human inteferon is more effective against herpes simplex virus than would be expected by simply adding the effectiveness of the two active ingredients. It is believed that this synergistic effect retards recurrent attacks of the virus.
~n another embodiment, this inven~ion comprises a cos-metic composition containing effective amounts of human interferon, an antiviral surface active agent, and a physiologically acceptable cosmetic carrier. Additional components, for example, skin softeners, rnay be included in the cosmetic formulations.
Cosmetic formulations are known in the art and are usually hypoallergenic and pH controlled. The cosmetic formula-tions of this invention are used as a prophylactic to prevent outbreak of herpetic lesions. They may be applied L9~
nightly. Cosme~ic formulations according to the present inven-tion generally containing less hurnan interferon and antiviral surface active agent than pharmaceutical preparations. The preferred range of human interferon is 103-105 I.U. and the preEerred range of the antiviral surface active agent is preferred A typical cosmetic formulation according to the present invention is the following:
Co~smetic Cream ~e~swax 12.1%
spexmaceti 12.6%
sweet alm~nd oil 54.4%
ho~ax 0.5~
rose water 19.4%
- onyxol 1.0%
human leu~ocyte interferonlo3-lo5 I.U-The following examples are presented in further illustra-tion of the practices of the present invention:
Example 1 To determine whether human interferon is compatible with antiviral surface active agents, monolayers of human embryo cells were grown. Human leukocyte interferon ~105 I.U.) was mixed with a 1% solution of nonylphenoxy-~olyethoxy ethanol (without a carrier) and with a pro-prietary cream formulation containing 1% nonylphenoxy-polyethoxy ethanol (Stearox). The interferon was kept in contact with the nonionic antiviral surfactant over-3n night and the mixture was then diluted 1:104 with astandard medium saline solution. The mix-ture was then applied to the monolayers of human embryo cells overnight at 37C. The next day the human embryo cells were exposed to vesicular stomatitis virus and after a suitable period ; 35 of time the cultures were assayed for virus plaques. The assays were compared to assays taken when the cells were *Trade mark ,~.
13~
.. .~
exposed to vesicular stomatitis virus without the benefit of any antiviral agent and with the benefit of human leukocyte intereron along (diluted as above). The results demonstrate that there is no reduction in activ-ity of human interferon when combined with the nonionicsurface active agent.
Example 2 The procedure of Example 1 was followed except that the human embryo cells were exposed to herpes simplex virus types 1 and 2 instead of vesicular stomatitis virus. The results demonstrate that human interferon remains active against herpes simplex virus in the presence of an anti-viral surface active agent. The tests show that humaninterferon is compatible with an antiviral surface active agent.
Example 3 Patient A, a female, suffers recurrent herpes simplex virus infections of the face. Lesions erupt approximately every 3 to 4 months and cover most of her face. The next time she feels a tingling sensation indicating the pro-dromal stage of viral multiplication, she applies thepharmaceùtical lotion described above directly to her entire face. The lotion is applied every 2 hours while she is awake for 3 days. The tingling sensation dis-appears within an hour after the first application. Two days after the first application, a small blister appears on her lip. The blister disappears a day later leaving no scar. ~atient does not xeport any subsequent outbreaksO
USE OF THESE COMPOSITIONS IN THE TREATMENT
OF HERPETIC INFECTIONS, PRE-~ALIGNANT SXIN
LESIONS, SKIN MALIGNANCIES AND PSORIASIS
BACXGROUND OF THE INVENTION
This invention relates to a composition and a method for treating herpes simplex infections in humans. More particularly, this invention relates to a pharmaceutical composition containing interferon and an antiviral surface active agent, and to a method for treating ~erpes simplex infectlons in humans by topically administering said pharmaceutical composition to the affec~ed area.
Infections by herpes simplex virus are extremely common in humans. The virus is transmitted by direct contact with infected individuals and it is estimated that more than half the human population has been infected by herpes simplex virus at one time or another.
Once an individual is infected, the virus manifPsts itself as sores or lesions on various parts of the body. Herpes labialis is the most clinical form of herpes simplex virus infection. The symptoms include inflammation of the mouth and gums as well as mouth eruptions (cold sores)~ The cold sores are often painful and unsightly.
In another common clinical form, herpes genitalis, eruptions occur in the genital area. Herpes genitalis is a serious problem. It often causes severe psycho-logical and social problems in afected individuals.
It can be ~atal to patients with deficient immune systems. In addition, it presents the risk of infections to the newborns of infected mothers, often a fatal disease to the infant.
~3¢3~
Herpes simplex virus may also infect the eye producing acute kera~itls, and may infect the central nervous system resulting in severe encephalitis.
Although it was once thought that there was only one type of herpes simplex virus, it is now known that there are two major types of the virus. Herpes simplex virus type 1 (hereinafter HSV-l) is usually associated with herpes labialis. Herpes simplex virus type 2 (hereinafter HSV-2) is usually associated with herpes genitalis.
However, HSV-l has been isolated in some instances from genital lesions, while HSV-2 has been isolated from lesions on parts of the body other than the genitals.
In some reports, HSV-l has been linked to lip cancer while HSV-2 has been linked to cervical and vulvar cancer.
Following the initial infection with either HSV-l or HSV-2 lesions may or may not appear. However, the virus does not die but continues to reside in a latent form in the nerve ganglia. Recurrent attacks may occur throughout life in response to non-specific stimuli, for example, in response to changes in body temperature, stress, ultra-violet radiation, hormonal changes, etc. It is believed by some ~hat recurrent attacks occur when the host's immune system is suppressed. At that time, virus latent in the ganglia travels along the nerve cells without damaging them until it emerges from ~he ends of the nerves. As it emerges, the virus infects the adjacent cells and begins to multiply.
Viral multiplication takes place in two stages eventually resulting in a lesion. In the first stage, known as the prodromal stage, the number of viral particles increases until a first maximum is reached. During this stage, the ~ ~3~
~ 3--patient may feel a tingling sensation at the site o viral multiplication. The nubmer of viral particles decreases thereafter. ~bout two to three days after the prodromal stage, the viral particles undergo a second stage of multiplication. In the second stage, number of viral particles increases until a second maximum, much larger than the first maximum, is reached.
The second stage of multiplication causes the death of many cells and results in a lesion. Usually, the lesion heals within 10 to 14 days but in some cases the lesion can last much longer.
Many claims have been made for effective antiherpetic compositions. Undoubtedly, the benefits demonstrated by many of these compositions in in vivo tests may be attributed to a placebo effect. This effect may be as high as 50~ for herpes simplex viral infections. One group of chemical agents which proved effective against herpes simplex virus in in vitro tests is the group comprising lipid-dissolving anionic and cationic surface active agents. The effectiveness of these ayents has been attributed to their ability to dissolve the lipid-; containing membrane which surrounds the nucleocapsid of both HSV-l and HSV-2.
More recently, it has been discovered by one of the inventors herein along with others that nonionic surface active agents are also effective in reducing the infectiv-ity of herpes simplex virus. For example, in Asculai, S.S., et al, Antimicrobial Agents and Chemotherapy, 13, 686 (1978), it is reported that certain nonionic surface active agents rapidly reduced the infectivity of HSV-l and HSV-2 in vitro. The nonionic surface active agents which inactivated the infectivity of herpes simplex virus were those possessing ether or amide linkages between the hydrophilic and the hydrophobic portions of the molecule.
See also U.S. 4,020,1~3 (Asculai et al) and U.S. 4,139,630 ~Asculai et al). The therapeutic effect of these nonionic s~rfactants was also a~tributed to their abili~y to dissolve the lipid~containing envelope of herpes simplex virus. The nonionic surfactants were also r~ported to destroy partially the nucleocapsid of the virus. The nonionic surfactants find use as spermicides in vaginal contraceptives. Contraceptive formulations containing nonionic surfactants were also demonstrated to be effective against herpes simplèx virus.
The treatment of herpes simplex virus infections by topical administration of surface active agents,whether anionic, cationic, or nonionic, does not produce entirely 15 satisfactory results. The most beneficial results are obtained when the surfactant is applied during the pro-dromal sta~e before the lesion appears. However, it is often difficult to tell when the virus is in the prodromal stage of multiplication. Furthermore, the surface active agent is applied to the uppermost layer of infected cells.
Because of the dilution efect, the cells below the uppermost layer do not receive sufficient amounts of the surface active agent to destroy the viral particles.
Thus, no protection is provided for cells below the surface layer and herpes simplex virus continues to multiply in those cells below the surface layer.
Additionally, treatment with the antiviral surface active agent does not appear to reduce the requency of recurrent attac~s. It is believed, however, that recurrent attacks might be prevented if suf f icient numbers of the multiplying viral particles are destroyed.
It would thus be desirable to provide a pharmaceutical composition which reduces the load of herpes simplex virus so that latency is not reestablished.
q;-~13 It would also be desirable to provide a pharmaceutical composition which prevents spread of the virus to cells below the surace layer.
Human interferon is known to protect cells against viral infections. Human interferon is produced by cells in reaction to the presence of specific inducers, such as viruses. It may be produced ln vivo by the cells of living organisms, or it may be produced in vitro by cell cultures in response to the presence of the inducer. There are now known to be three main varieties cf human interferon: leukocyte or ~ , fibro-blast or ~, and immune or y interferon. There are also known to be several sub- varieties of human leukocyte and fibroblast interferon~
Human interferon is relatively nontoxic and nonantigenic in humans. It is also extremely effective against a broad spectrum of viruses, including herpes simplex virus, even at very lo~- concentrations Until the present, treatment of herpetic lesions with human interferon has proceeded along two main courses: a) medi-cinal induction of endogenic interferon in the patent, and b) administration of exogenic interferon to the patient.
For example, U.S. 4,053,582 (Stickl) discloses a method for treating herpes simplex infections in humans by administering attenuated fowl pox virus to the patient.
The attenuated virus induces the patient to produce his own interferon. The herpetic lesions heal within a short time after induction.
U.S. 4,061,538 (Dorner et al) and 4,184,917 (Dorner et al) disclose a method of treating herpes simplex viral infections by administering structurally modified 3~
interferons to the patient. In these patents, the modified interferons are administered systemisally to the patient.
Several published reports also disclose the treatment of herpetic eye infections by topical administration of human interferon. For example, see D. Naumann-Haefelin et al in Infection and Immunity, 17, 468 (1977) and B. R. Jones et al in Lancet ii, 128 (1976).
None of these disclosures suggests the treatment of herpes labialis and herpes genitalis in humans by administering topically an interferon-containing pharmaceutical composition. Moreover~ none of these disclosures suggests the treatment of herpes simplex viral infections by administering topically a combina-tion of human interferon and an antiviral surface active agent.
This invention also relates to a method for treatment of skin malignancies and pre-malignant skin lesions, including squamous cell carcinoma, basal cell carcinoma, actinic keratosis, and leukoplakia. This invention also relates to a method for treatment of psoriasis and herpes zoster.
3..3 ~3~
Basal cell carcinomas, which ma~f appear as small, shiny, firm nodules or ulcerated crusted lesions on the skin, are generall~ treated by electrodesicca-tion and curettage, surgical excision or X-ray therapy~ In about 5% of cases ~ recurrences occur.
Such recurrences are treated typically with further excision or Moh's chemosurgery, i.e., microscopically controlled excision after chemical fixation of the tissue.
10 - .
Squamous cell carcinoma arises from the malpighian cells of the epithelium. The tumor generally begins as a small red papule or plaque with a scaly or crusted surface. Subseque~tly, it becomes nodular.
Eventually, the lesion ulcerates and invades the underlying tissue. As with basal cell carcinoma, squamous cell carcinoma is treated with electro-desiccation and curettage, surgical excision or X-ray therapy.
Precancerous keratotic lesions, actinic keratoses, are the frequent consequence of many years of over-exposure to sunlight. The keratoses are usually hard, and gray to dark in color. Such lesions are ~5 generally treated by topical application of fluoro-uracil (5-fluorouxacil). However, if the lesions become malignant, topical application of fluoroura-cil is not recomme~ded as the rate of recurrence is unacceptably high with such therapy.
3~
Leukoplakia~ hyperkerati.nizatlon of th~ oral mucosa, is generally believed to result from several factors, local or systemic, ac~ing independently or in com-~ination, such as: tobacco, alcohol, chronic irrita-tion from such causes as cheek biting, ill-fitting dentures, shaxp, broken or worn--down teeth or spicy foods, syphillis, vitamin deficiency, hormonal changes and C~ndida a~bicans. Leukoplakia lesions vary from a small, well-localized white patch to a`diffuse area involving much of the oral ~ucosa, and from a smooth, flat, or slightly elevated, translucent white plaque to a thic~, fissured papillomatous lesion that is firm to palpation. Treatment of leukoplakia generally comprises initial removal or elimination of any recogniz-able irritating factors, such as tobacco or faultyrestoration or pros~hetic devices, to chemical irri-tants, and total excision or cauterization of the localized lesions. Large lesions may be removed by a series of "stripping" operations. The patient should additionally be re-examined periodically and any lesions subsequently located biopsied because of the pre-cancerous nature of the disease. Additionally, leu~oplakia may be involved in lesions of -the vulva and anus~ When involved wlth the vulva, leukoplakia is treated by total vulvectomy.
Psoriasis is characterized by skin lesions which are sharply demarcated, usually non-pruritic, erythematous papules or plaques covered with overlapping, silvery 3Q or slightly opalescent, shiny scales. The typical course of psoriasis is chronic remission and recur-rence, which vary in frequency and duration. Psoria-sis varies in severity from one or two lesions to a widespread dermatosis, to psoriatic arthritis or exfoliation. Treatment depends upon the extent and :3.'~ 3~
severity of the involvement. The simplest form of trea~ment, topical application of lubricants, kerato-lytics and corticosteroids, is initially employed.
Systemic antimetabolltes should be used only in severe 5 skin or joint involvemen-t because of their potential adverse effects. Exposure to ultraviolet light has bPen found helpful in the treatment of psoriasis.
~lethotrexate taken orally is generaLly an effective treatment in severe disabling psoriasis which has not responded to topical therapy. However, because of the toxicity of met~otrexate, hematological, renal and hepat-ic functions of the patient must be carefully monitored.
Herpes zoster is a virus-related, acute CNS infection involving primarily the dorsal root ganglia, and characterized by vesicular eruption and neuralgic pain in the cutaneous area supplied by peripheral sensory nerves arising in the affected root ganglia.
Herpes zoster may be activated by local lesions or bY
systemic disease, among other reasons. Prodromal symptoms of chills and fever, malaise and ~I dis-turbances may be present for three or four days be-fore the distinctive features of the disease develop.
On about the fourth or fifth day, characteristic crops of vesicles on an erythematous base appear, following the cutaneous distribution of one or more posterior root ganglia. There is no specific treat-ment for herpes zoster. ~arly systemic application of a corticosteroid, however, generally relieves pain.
It would thus be desirable to provide a method for treatment of malignant and pre-malignant skin lesions, which comprises topical administration of an effective agent.
It would also be desirable -to provide an effective method for treatment of malignant and pre-malignant skin lesions which employes topical application of a non-toxic agent.
It would also be desirable to provide an effective method for treatment of psoriasis comprising topical administration of a non-toxic and relatively non-antigenic agent.
It would further be desirable to provide a method for treatment of herpes zoster comprising topical adminis-tration of an effective, therapeutic agent.
Human interferon is known to protect cells against viral infection. Human interferon is produced by cells in reaction to the presence of specific inducers, ,uch as viruses. It may be produced in vivo by the cells of living organisms, or it may be produced in vitro by cell cultures in response to the presence of the inducer. There are now known to be three main varieties of human interferon: leukocy~e (~3, fi~ro-blast (~) and immune (y). Additionally, there are also known to be several subvarie-ties of human leuko-cyte (a) and fibroblast (~) interferon.
Human interferon is nontoxic and relatively nonanti-genic in humans. It is an effective agent against a broad spectrum of viruses, including herpes simplex virus. For example, U.S. Pat. No. 4,061,538 (Dorner et al.) and U.S. Pat. No. 4,184,917 (Dorner et al.) disclose a method of treating herpes simplex viral infections by ~m; ni stering structurally modified interferons to the patient. The method of adminis-tration disclosed in the Dorner patents is systemic.
~ 3~
Several published reports also disclose treatment of herpetic eye infections by ~opical administra~ion of human interferon~ For example, see D. Na~nann-Haefelin et al~ in Infection ~nd Immunity, 17:458 (1977) and B. R. Jones et al. in La~cet i~ :128 (1976).
It has also been recently discovered that nonionic surace active agents (such as are employed as spermicides in ~aginal contraceptives) are effective in treatment of viral skin diseases. For example, in Asculai, S.S. et al; An~imicrob~a~ Agents ~d Chemother~py, 13:686 ~1978), it is reported that cer-tain nonionic surface active agents rapidly reduce the infectivity of herpes simplex ~iruses (HSV-1 and lS HSV-2) in vitro~ The nonionic surface active agents which inactivated the infPctivity of the viruses were those possessing e-ther or amide linkages between the hydrophilic and the hydrophobic portions of the molecule. See also U.5. Pat. No. 4,020,183 (Asculai et al.) and U.5. Pat. No. 4,139,630 (Asculai et al.) The therapeutic effect of such nonionic surfactants was attributed in part to their potential to dissolve the lipid-conta;ni ng envelope of the virus. The non-ionic surfactants were also reported to partially dest~oy the nucleocapsid of the virus.
B
Accordingly, it is an object of the ~resent inv~ntion to provide novel pharmaceutical compositions containing human interferon and an antiviral surface active agent.
It is also an object of the present invention to provide a method for treating lesions due to herpes simplex virus by topically administering the aforesaid pharmaceutical compositions.
I~ is a further object of the present invention to provide compositions for treating herpetic lesions which not only heal the lesions but may also reduce recurrent attacks.
I-t is another object of the present invention to provide a method for treatment of malignant and pre-malignant skin lesions, herpes zoster and psoriasis.
It is also an object of the present invention to provide a method of treatment of skin malignancies and pre-malignant lesions, herpes zoster and psoriasis which comprises topical treatment of the affected skin area with a pharmaceutical composition.
It is another object of this invention to provide a method for treatment of malignant and pre-malignant skin lesions by topical administration of a nontoxic pharmaceutical composition.
It is a further object of this invention to provide a method for treatment of skin lesions produced by squamous cell carcinoma, basal cell carcinoma, actinic keratosis, leukoplakia, psoriasis and herpes zoster which comprises administration of a relatively nonantigenic pharma-ceutical preparation.
B
13~How these and other objects of this invention are achieved will become apparent in light of the accom-panying disclosure and claims.
5 SUM~l~Y OF THE INVENTION
A composltion fox treating herpes simplex viral infec-tions comprises about 102 to 103 I.U. of human inter-feron, about 0.1% to 20% hy weigh~ of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, a composition for treating herpes simplex viral infections comprises about 104 to 106 I.U. human leukocyte interferon, about 1% to 5% by weight of a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carxier. Amethod for treating herpes simplex viral infections in humans comprises topically administer-ing to the affected area an effective amount of said compositions. Most preferably, a method for treating herpes simplex viral infections in humans comprises topically administering to the affected area an effective amount of said compositions during the pro-dromal stage of viral multiplication.
A method for treating skin malignancies, pre-malignant skin lesions, and lesions associated with psoriasis and herpes zoster comprises topically administering to the affected skln area an effective amount of a compo-sition comprising about 102-lO~ IU of human interferon, about 0.1% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier-The topical administration could be achieved by direc~
application of the pharmaceutical product with or with-out an occlusive dressin~. The method of treatment for malignant and pre-malignant skin lesions would preferably involve daily application of a composition containing human interferon and an antiviral surface~
active agen~ with an occlusive dressing. Such treatment o~ the lesions would pxeferably continue for ten days, at which point evaluation of the trea-tment would be madQ.
DETAILED DESCRIPTION OF THE INVENTION
The novel pharmaceutical compositions of the present invention contain effective amounts of human interferon, an antiviral surface active agent, and a physiologically acceptable carrier. The pharmaceutical compositions may contain any of the known varieties or sub-varieties of human interferon~ Thus, the composition may con~aining human leukocyte, fibroblast, or immune interferon. Additionally, the interferon may suitably be prepared by "classical" culture methods or by recom-binant DNA methods. An effective dosage of human inter-feron for treating herpetic lesions in accordance with the practices of the present invention is about 10Z to loB, preferably about 104 to 106, I.U.
The antiviral surface active agent may be anionic, cation-ic, or, preferably, nonionic. Antiviral surface active agents are known in the art. These surfactants dramati-cally reduce the infectivity of HSV-l and HSV-2 by damag-ing or destroying the lipid envelope of the virus.
Suitable anionic surfactants include sodium alkylsulfon-ates and sodium alkylbenzenesulfonates. Suitable cationic surfactants include quaternary ammonium detergents, such as cetyl pyridinium chloride, and benz-alkonium chlorides.
Nonionic surface active agents are preferred in the pharmaceutical preparations of of the present invention.
~15-- , In contrast to cationic, anionic, and ampholytic surface active agents, the nonionics containing no ionizable groups and have no surface charge. They depend upon their entire molecule for surface activity. Almost any hydrophobic compound which has in its structure a carboxy, hydroxy, amido or amino group with a free hydrogen attached to the nitrogen, can be reacted with ethylene oxide to form a nonionic surfacant. At least three groups of nonionic surfactants are recognized:
1~ a) those having an ether linkage between the hydrophilic and hydrophobic portions of the molecule, b) those having an ester or ether-ester linkage, and c~ those having an amide linkage. Nonionic surfactants having at least one ether or amide linkage are preferred for pur-poses of the present invention. Examples of preferrednonionic surfactants include the following: nonyl-phenoxy-polyethoxy ethanol (available under the trade name Nonoxynol-9), p-diisobutylphenoxypolyethoxy ethanol (available under the trade name Triton X-100), polyoxyethylene (10) oleyl ether (available under the trade name Brij-97), and onyx-ol (available under the tradename Onyx-ol 345).
An effective dosage of an antiviral surface active agent for purposes of the present inventions comprises about 0.1% to 20% by weight of the pharmaceutical composition~ The preferred range is about l~ to 5% by weight.
The balance of the pharmaceutical compositions comprises an inert, physiologically acceptable carrier. The carrier should not react with the active ingredients and not reduce their effectiveness. Suitable physiologically acceptable carriers include water t ethanol, polyethylene glycol, mineral oil, petrolatum, propylene glycol, and ~ 16-the like. The pharmaceutical compositions are prefer ably administered in lotion, cream, oil, or emulsion fo.rmulations.
The following are examples of suitable formulations containing a nonionic surfactant and human interferon:
Pharmaceutical Lotion propylene glyool 24.75 ml.
~riethanolamine l.00 ml.
water 7.00 ml.
oleic acid 1.50 gm.
polyethylene glycol monostearate lO.50 gm.
silicon fluids lO.. 00 ml.
carbopol-934 (2% mucilage)50.00 ml.
human leukocyte in~erferon~0-lO8 I
Pharmaceu~ical Cream ~
white petrola~um 41.00 gm microcrystalline wax 3.00 gm flUid lanolin lO.00 gm 50~bitan monooleate 4.75 gm p~lysorba~e-80 0.25 gm purified water - 41.00 ~
huma~ leukocyte in~erferonlOÇ-lO- I.U.
Pharmaceu~ical Cream B
~permaCQti 7~5~
white wax 12.0%
mineral oil 56 . 096 sodium bora~e O. 5~
sor~itan monooleate 5. 0%
water 19 Og~
hu~narl leukocyte interferon10 ~-lQ7 I .U .
.3~3~ 3 Topical administration oE pharmaceutical compositions of the present invention may be effec~ed by applying a small amount (e.g., about 1 ml) of the compositions directly to and in areas adjacent to the site of the lesions with a cotton swab, soft brush, sponge or the like. Any quantity sufficient to cover the area of the lesions is effective. 'rreatment with the pharmaceutical compositions herein disclosed should be fre~uent, for example, every 2-4 hours, for about 3-4 days. Preferably, the pharmaceutical compositions are applied during an early stage o viral multiplication. For example, the compositions may be applied during the prodromal stage in the areas wherP a tingling sensation is felt. When the compositions are applied to lesions, the pain is substantially reduced within 1 hour in almost all cases.
The lesions are noticeably improved within 4 to 12 hours, and are completely healed within 4 to 5 days with little or no scarring. When the compositions are applied during the prodromal stage, the tingling sensation usually disappears within the hour and the compositions provide a prophylaxis against emergence of the lesions. In some cases, no lesion appears at all; in other cases a small blister appears which disappears within 2-3 days.
Additionally, treatment of herpes simplex virus infec-tions in accordance with the present invention appears toreduce the frequency of recurrent attac~s and in some cases apparently eliminates the virus altogether. No contraindications have been found.
The pharmaceutical compositions of the present invention also display antimicrobial activity as well as antiviral activity. For example, they are effective in treating warts as well as bacterial infections. As used herein herein, the term antimicrobial activity refers to activity against microorganisms other than viruses such as bacteria and fungi.
In addition to direct application, the pharmaceutical compsoitions may be administered topically by various other methods. For example, the compositions may be delivered to the affected region in microencapsulated form. They may also be deliv red in a foam, by spray, tampon, vaginal suppository, etc.
Although it is not completely understood, it i5 believed that the pharmaceutical compositions herein disclosed operate in the following manner. The antiviral surface active agent dissolves the lipid-containing envelopes of herpes simplex virus thereby destroying its infectiv-ity. The interferon aids the cells in preventing viral replication. In addition, because very few interferon molecules are needed to protect a cell, the interferon prevents the spread of the virus to cells below the uppermost layer. Thus, the combination of a surface active agent, such as a nonionic surface active agent, and human inteferon is more effective against herpes simplex virus than would be expected by simply adding the effectiveness of the two active ingredients. It is believed that this synergistic effect retards recurrent attacks of the virus.
~n another embodiment, this inven~ion comprises a cos-metic composition containing effective amounts of human interferon, an antiviral surface active agent, and a physiologically acceptable cosmetic carrier. Additional components, for example, skin softeners, rnay be included in the cosmetic formulations.
Cosmetic formulations are known in the art and are usually hypoallergenic and pH controlled. The cosmetic formula-tions of this invention are used as a prophylactic to prevent outbreak of herpetic lesions. They may be applied L9~
nightly. Cosme~ic formulations according to the present inven-tion generally containing less hurnan interferon and antiviral surface active agent than pharmaceutical preparations. The preferred range of human interferon is 103-105 I.U. and the preEerred range of the antiviral surface active agent is preferred A typical cosmetic formulation according to the present invention is the following:
Co~smetic Cream ~e~swax 12.1%
spexmaceti 12.6%
sweet alm~nd oil 54.4%
ho~ax 0.5~
rose water 19.4%
- onyxol 1.0%
human leu~ocyte interferonlo3-lo5 I.U-The following examples are presented in further illustra-tion of the practices of the present invention:
Example 1 To determine whether human interferon is compatible with antiviral surface active agents, monolayers of human embryo cells were grown. Human leukocyte interferon ~105 I.U.) was mixed with a 1% solution of nonylphenoxy-~olyethoxy ethanol (without a carrier) and with a pro-prietary cream formulation containing 1% nonylphenoxy-polyethoxy ethanol (Stearox). The interferon was kept in contact with the nonionic antiviral surfactant over-3n night and the mixture was then diluted 1:104 with astandard medium saline solution. The mix-ture was then applied to the monolayers of human embryo cells overnight at 37C. The next day the human embryo cells were exposed to vesicular stomatitis virus and after a suitable period ; 35 of time the cultures were assayed for virus plaques. The assays were compared to assays taken when the cells were *Trade mark ,~.
13~
.. .~
exposed to vesicular stomatitis virus without the benefit of any antiviral agent and with the benefit of human leukocyte intereron along (diluted as above). The results demonstrate that there is no reduction in activ-ity of human interferon when combined with the nonionicsurface active agent.
Example 2 The procedure of Example 1 was followed except that the human embryo cells were exposed to herpes simplex virus types 1 and 2 instead of vesicular stomatitis virus. The results demonstrate that human interferon remains active against herpes simplex virus in the presence of an anti-viral surface active agent. The tests show that humaninterferon is compatible with an antiviral surface active agent.
Example 3 Patient A, a female, suffers recurrent herpes simplex virus infections of the face. Lesions erupt approximately every 3 to 4 months and cover most of her face. The next time she feels a tingling sensation indicating the pro-dromal stage of viral multiplication, she applies thepharmaceùtical lotion described above directly to her entire face. The lotion is applied every 2 hours while she is awake for 3 days. The tingling sensation dis-appears within an hour after the first application. Two days after the first application, a small blister appears on her lip. The blister disappears a day later leaving no scar. ~atient does not xeport any subsequent outbreaksO
- 2 1 ~
EXCLmP1e 4 Patient B, a female suf~ers from recurrent attacks of herpes genitalis. On the average, outbreaks occur every 8 weeks and symptoms last for about 2 weeks. She is treated with the pharmaceutical cream A described above during the prodromal stage of her next outbreak. The cream i5 applied every 4 hours for 3 days. The tingling sensation disappears almost immediately and no eruptions axe subsequently observed. Recurrent outbreaks are also not.reported.
Example S
Patient C, a male, suffers from recurrent attacks of herpes genitalis. Eruptions appear every 3-4 months on the average and la t about 10-14 days. At the next outbreak, a pharmaceutical cream 3 described above i5 applied a~ soon as the eruptions begin to appear. The pharmaceutical cream is applied every 2 hours. The eruptions are much smaller and fewer in number than usually appear and last for only 2 days~ Patient C
thereafter applies the cosmetic cream described above once a day. No subsequent outbreaks are reported~
-2~-The novel method of trea~menl of mali~nant skin lesions, pre-malignant skin lesions, and skin lesions associated with psoriasis ,~nd herpes zostex comprlses topical adminis~ration of an effective S amoun~ of a pharmaceutical composition con~aining : human interfer~n and an antiviral sur~ace active agent, contained in a physioloqically accePtable carri~r.
The inter~eron used in the pharmac~utical composi-~ tion may be any of the known varisties or subvari :~ 10 eties of human interferon. Thus, the phanmaceu~1cal composition may contain human leukocyte (~), fibro-blas~ (~), or ~mmune (y) in~erferon. Furthermore, the in~ereron may be prepared by cLassical culture methods or by recombinant D~A methods. An effective dosage of human interferon for treating the s~in lesions in accordance with the practices of the presen~ invention ig about 102-108 IU and pre~erably 104 10~ IU.
The antivlral surface active agen~ of the pharmaceu~i-- cal composition may be anionic, ca~ionic, or, prefer-ably, ~onionic. Antiviral surface ac~ive agents are known in the art. Suitable anionic sur~actants in-clude sodium alkylsulfonates, and sodium alkylbenzene-sulonates. Suitable cationic sur~actants include~uaternary ammonium detergen~s, such as ce~yl pyridinium chloride and benzalkonium chlorides.
Nonionic surface active agents are preerred in ~he p~armaceutical ~reparations employed with the me~:~od of the present invention. In contrast to cationic and anionic (and also am~nolytic) sur-ace active agents, the nonionics con-tain no ionizable groups and have no surface charge. They depend upon t~eir entire molecule ~or surface ac-tivity. Almcst any hydrophobic compound which ~as in its structure a carboxy, hydroxy, amido or amino group with a Eree hydrogen attached to the nitro~en, can ~e reacted with ethylene oxide to form a nonionic surfactant.
At leas~ three gro~ps of nonionic surfactants are recogni~ed: (a) those having an ether linkage ~etT.~een the hydrop'nilIc and hydrophobic portions of the molecule; ~b) those having an ester or ether-ester linkage; and (c) those having an amide linkage. Ncn-ionic s~r,~ctants ha~ing at least one ether or amide linkage are pre~erred for purposes of the present in-vention. Examples of such preferred nonionic sur-factants include the following: nonylphenoxy-poly-ethoxy ethanol (available under the trade name Nonoxynol~9); p-diisobutylphenoxy-polyetho~y ethanol.
(available under the trade name Triton X-100)*; poly~
oxyethylene (10) oleyl ether (available under the trade namP Brij-97); and onyx-ol (available under the trade name Onyx-ol 345)*
An effective amo~nt of a~ antiviral surface active agent in a pharmaceutical composition employed in the method of the present invention comprises about 0.1 to 20~ by weight of the pharmaceutical composition.
The pre~erred range is about l~ to about 5~ by weight.
The balance of the pharmaceutical composition employed in the method of the pre5ent invention comprises an inert, physiologically acceptable carrier. The carrier should not react with or other~se reduce the effectiveness of the active ingredients. Suitable physiologically acceptable carriers include: water;
*Trade mark ~3~3 --2~-ethanol; polyethylerle ylycoli mineral oil; pe'crolatum;
propylene glycol; and the llke~ The pharmaceutical compositions are preferably prepared in lotion, cream, oil or emulsion formulations for administration in S accordance with the present invention.
The treatment of skin malignancies such as squamous cell carcinoma and basal cell carcinoma and pre-malignant lesions such as actinic keratosis and leuko-plakia according to the present invention involves topical application of a pharmaceutical composition containing an effective amount of human interferon and antiviral surface active agent, such as described above.
The topical administration could be accomplished with or without an occlusive dressing, but preferably with an occlusive dressing. The lesions are preferably treated daily for a period of about ten (10) days by topical adminlstration of a pharmaceutical composition containing inter~eron and an antiviral suxfactantO
After such time, the lesions would be evaluated and a determination made whether further or continued treat-ment should be undertaken. For example, observation should be made for improvement in lesions or for pos-sible new lesions.
The present method of treatment is also useful in cases where squamous or basal cell carcinomas have been surgically removed, but the tumor margins of the specimen showed tumor cells. The present method would ,~.
be employed as a form of prophylac~ic therapy, with monitoring for recurrences.
Althouqh ten (10) day courses of daily application with an occlusive dressing are preferable in the treatment of malignant and pxe~malignant skin lesions, modifica-tions can be readily made as necessary in treatment of specific cases.
In treatment of herpes zos~er accor~ing to the present invention, topical application, preferably with an occlusive dressing, would be made of a pharmaceutical composition containing interferon and an antiviral surfactant, as described above. Application would be made tw~ to three times daily until there was evidPnce of healing. By using the method of the present inven-tion, pain associated with herpes zoster is alleviated because of local healing. Additionally, use of the method of the present invention in treatment of herpes zoster has been found to prevent postherpetic neuralgia.
The lesions associated with herpes zoster have been determined to heal faster than if left untreated using the method of the present invention.
In the treatment of psoriasis according to the present invention, repeated courses of topical application of interferon and an antiviral surfactant in a physio-logically acceptable carrier according to the present invention would be requiredO Psoriasis is a chronic, recurring condition, for which there is no known cure.
Since large areas of the skin are often involved, a plastic occlusive dressing would preferably be used to insure absorption into the skin of the pharmaceutical ~6--composition containlng human interferon and an an~i-viral surfactan~. ~dditionally, since large areas ma~
be involved and hence require treatment, a significant amount of the human interferon would be absorbed in~o the bloodstream. Such may have a favorable effect on the systemic aspects of psoriasis, i.e., psoriatic arthritis.
Topical administration according to the present inven-tion may be effected by applying a small amount (e.g., about 1 ml) of the compositions containing human inter-feron and an antiviral surfactant directly to and in areas adjacent to the site of lesions with a cotton swab, soft brush, sponge, or the like. The quantity lS applied would be dependent on the size of the lesions being treated. Any quantity sufficient to cover the area of the lesions is effective.
In addition to direct application, the pharmaceutical compositions containing h~man inter~eron and an anti-viral surfactantimay be administered topically by various other methods. For example, the compositions may be delivered to the affected skin region in micro-encapsulated form. The pharmaceutical compositions may also be delivered in a foam, by spray, suppository, etc.
In another embodiment, this invention comprises treat-ment of the malignant or pre-malignant skin lesions, psoriasis and herpes zoster with a cosmetic composi-tion containing effective amounts of human interferon, an a~tiviral surface active agent, and a physiologi-cally acceptable cosmetic carrier. Additional com-ponents, for example, s~in softeners, may be included in the cosmetic formulation. Cosmetic formulations are known in the art and are usually hypoallergenic and pH
controlled~ Cosmetic ~ormulations according to the present invention contain less human interferon and antiviral surface active agent than pharmaceutical preparations. The preferred range of dosage o~ human interferon is 103-lOS I.U. and the preferred range of amount of antiviral surface active agent is 0.1% to 1~ by weight in the composition. A nonionic antiviral surface agent again is preferred.
As indicated hereinabove, the interferon-containing compositions of this invention are also useful as a prophylactic for and in the treatment of in situ cervical carcinoma. In this application the interferon-containing compositions would be applied directly to the cervical or genital area While the invention has been described by reference to speci~ic embodiments, this was for the purpose of illustration only and should not be construed to limit the spirit or scope of the disclosure of this invention.
EXCLmP1e 4 Patient B, a female suf~ers from recurrent attacks of herpes genitalis. On the average, outbreaks occur every 8 weeks and symptoms last for about 2 weeks. She is treated with the pharmaceutical cream A described above during the prodromal stage of her next outbreak. The cream i5 applied every 4 hours for 3 days. The tingling sensation disappears almost immediately and no eruptions axe subsequently observed. Recurrent outbreaks are also not.reported.
Example S
Patient C, a male, suffers from recurrent attacks of herpes genitalis. Eruptions appear every 3-4 months on the average and la t about 10-14 days. At the next outbreak, a pharmaceutical cream 3 described above i5 applied a~ soon as the eruptions begin to appear. The pharmaceutical cream is applied every 2 hours. The eruptions are much smaller and fewer in number than usually appear and last for only 2 days~ Patient C
thereafter applies the cosmetic cream described above once a day. No subsequent outbreaks are reported~
-2~-The novel method of trea~menl of mali~nant skin lesions, pre-malignant skin lesions, and skin lesions associated with psoriasis ,~nd herpes zostex comprlses topical adminis~ration of an effective S amoun~ of a pharmaceutical composition con~aining : human interfer~n and an antiviral sur~ace active agent, contained in a physioloqically accePtable carri~r.
The inter~eron used in the pharmac~utical composi-~ tion may be any of the known varisties or subvari :~ 10 eties of human interferon. Thus, the phanmaceu~1cal composition may contain human leukocyte (~), fibro-blas~ (~), or ~mmune (y) in~erferon. Furthermore, the in~ereron may be prepared by cLassical culture methods or by recombinant D~A methods. An effective dosage of human interferon for treating the s~in lesions in accordance with the practices of the presen~ invention ig about 102-108 IU and pre~erably 104 10~ IU.
The antivlral surface active agen~ of the pharmaceu~i-- cal composition may be anionic, ca~ionic, or, prefer-ably, ~onionic. Antiviral surface ac~ive agents are known in the art. Suitable anionic sur~actants in-clude sodium alkylsulfonates, and sodium alkylbenzene-sulonates. Suitable cationic sur~actants include~uaternary ammonium detergen~s, such as ce~yl pyridinium chloride and benzalkonium chlorides.
Nonionic surface active agents are preerred in ~he p~armaceutical ~reparations employed with the me~:~od of the present invention. In contrast to cationic and anionic (and also am~nolytic) sur-ace active agents, the nonionics con-tain no ionizable groups and have no surface charge. They depend upon t~eir entire molecule ~or surface ac-tivity. Almcst any hydrophobic compound which ~as in its structure a carboxy, hydroxy, amido or amino group with a Eree hydrogen attached to the nitro~en, can ~e reacted with ethylene oxide to form a nonionic surfactant.
At leas~ three gro~ps of nonionic surfactants are recogni~ed: (a) those having an ether linkage ~etT.~een the hydrop'nilIc and hydrophobic portions of the molecule; ~b) those having an ester or ether-ester linkage; and (c) those having an amide linkage. Ncn-ionic s~r,~ctants ha~ing at least one ether or amide linkage are pre~erred for purposes of the present in-vention. Examples of such preferred nonionic sur-factants include the following: nonylphenoxy-poly-ethoxy ethanol (available under the trade name Nonoxynol~9); p-diisobutylphenoxy-polyetho~y ethanol.
(available under the trade name Triton X-100)*; poly~
oxyethylene (10) oleyl ether (available under the trade namP Brij-97); and onyx-ol (available under the trade name Onyx-ol 345)*
An effective amo~nt of a~ antiviral surface active agent in a pharmaceutical composition employed in the method of the present invention comprises about 0.1 to 20~ by weight of the pharmaceutical composition.
The pre~erred range is about l~ to about 5~ by weight.
The balance of the pharmaceutical composition employed in the method of the pre5ent invention comprises an inert, physiologically acceptable carrier. The carrier should not react with or other~se reduce the effectiveness of the active ingredients. Suitable physiologically acceptable carriers include: water;
*Trade mark ~3~3 --2~-ethanol; polyethylerle ylycoli mineral oil; pe'crolatum;
propylene glycol; and the llke~ The pharmaceutical compositions are preferably prepared in lotion, cream, oil or emulsion formulations for administration in S accordance with the present invention.
The treatment of skin malignancies such as squamous cell carcinoma and basal cell carcinoma and pre-malignant lesions such as actinic keratosis and leuko-plakia according to the present invention involves topical application of a pharmaceutical composition containing an effective amount of human interferon and antiviral surface active agent, such as described above.
The topical administration could be accomplished with or without an occlusive dressing, but preferably with an occlusive dressing. The lesions are preferably treated daily for a period of about ten (10) days by topical adminlstration of a pharmaceutical composition containing inter~eron and an antiviral suxfactantO
After such time, the lesions would be evaluated and a determination made whether further or continued treat-ment should be undertaken. For example, observation should be made for improvement in lesions or for pos-sible new lesions.
The present method of treatment is also useful in cases where squamous or basal cell carcinomas have been surgically removed, but the tumor margins of the specimen showed tumor cells. The present method would ,~.
be employed as a form of prophylac~ic therapy, with monitoring for recurrences.
Althouqh ten (10) day courses of daily application with an occlusive dressing are preferable in the treatment of malignant and pxe~malignant skin lesions, modifica-tions can be readily made as necessary in treatment of specific cases.
In treatment of herpes zos~er accor~ing to the present invention, topical application, preferably with an occlusive dressing, would be made of a pharmaceutical composition containing interferon and an antiviral surfactant, as described above. Application would be made tw~ to three times daily until there was evidPnce of healing. By using the method of the present inven-tion, pain associated with herpes zoster is alleviated because of local healing. Additionally, use of the method of the present invention in treatment of herpes zoster has been found to prevent postherpetic neuralgia.
The lesions associated with herpes zoster have been determined to heal faster than if left untreated using the method of the present invention.
In the treatment of psoriasis according to the present invention, repeated courses of topical application of interferon and an antiviral surfactant in a physio-logically acceptable carrier according to the present invention would be requiredO Psoriasis is a chronic, recurring condition, for which there is no known cure.
Since large areas of the skin are often involved, a plastic occlusive dressing would preferably be used to insure absorption into the skin of the pharmaceutical ~6--composition containlng human interferon and an an~i-viral surfactan~. ~dditionally, since large areas ma~
be involved and hence require treatment, a significant amount of the human interferon would be absorbed in~o the bloodstream. Such may have a favorable effect on the systemic aspects of psoriasis, i.e., psoriatic arthritis.
Topical administration according to the present inven-tion may be effected by applying a small amount (e.g., about 1 ml) of the compositions containing human inter-feron and an antiviral surfactant directly to and in areas adjacent to the site of lesions with a cotton swab, soft brush, sponge, or the like. The quantity lS applied would be dependent on the size of the lesions being treated. Any quantity sufficient to cover the area of the lesions is effective.
In addition to direct application, the pharmaceutical compositions containing h~man inter~eron and an anti-viral surfactantimay be administered topically by various other methods. For example, the compositions may be delivered to the affected skin region in micro-encapsulated form. The pharmaceutical compositions may also be delivered in a foam, by spray, suppository, etc.
In another embodiment, this invention comprises treat-ment of the malignant or pre-malignant skin lesions, psoriasis and herpes zoster with a cosmetic composi-tion containing effective amounts of human interferon, an a~tiviral surface active agent, and a physiologi-cally acceptable cosmetic carrier. Additional com-ponents, for example, s~in softeners, may be included in the cosmetic formulation. Cosmetic formulations are known in the art and are usually hypoallergenic and pH
controlled~ Cosmetic ~ormulations according to the present invention contain less human interferon and antiviral surface active agent than pharmaceutical preparations. The preferred range of dosage o~ human interferon is 103-lOS I.U. and the preferred range of amount of antiviral surface active agent is 0.1% to 1~ by weight in the composition. A nonionic antiviral surface agent again is preferred.
As indicated hereinabove, the interferon-containing compositions of this invention are also useful as a prophylactic for and in the treatment of in situ cervical carcinoma. In this application the interferon-containing compositions would be applied directly to the cervical or genital area While the invention has been described by reference to speci~ic embodiments, this was for the purpose of illustration only and should not be construed to limit the spirit or scope of the disclosure of this invention.
Claims (32)
PROPERTY IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A therapeutic composition for treating herpes simplex viral infections in humans, comprising an effective amount of human interferon, an effective amount of a suitable antiviral surface active agent, and a physiologically acceptable carrier.
2. The composition of claim 1 wherein the amount of antiviral surface active agent is about 1% to 5%.
3. The composition of claim 1 wherein the antiviral surface active agent is nonionic.
4. The composition of claim 3 wherein the nonionic surface active agent has at least one ether or amide linkage.
5. The composition of claim 3 wherein the nonionic surface active agent is nonylphenoxy-polyethoxy ethanol.
6. The composition of claim 3 wherein the nonionic surface active agent is p-diisobutylphenoxy-polyethoxy ethanol.
7. The composition of claim 3 wherein the nonionic surface active agent is polyoxyethylene (10) oleyl ether.
8. The composition of claim 2 wherein the human interferon is leukocyte interferon.
- Page 1 of Claims-
- Page 1 of Claims-
9. The composition of claim 2 wherein the amount of human interferon is about 104 to 106 I.U.
10. The composition of claim 1 wherein the carrier includes water, ethanol, polyethylene glycol, mineral oil, petrolatum, or propylene glycol.
11. The therapeutic composition of claim 1 wherein said carrier is a pharmaceutically acceptable carrier.
12. The therapeutic composition of claim 1 wherein said carrier is a cosmetically acceptable carrier.
13. The composition of claim 1, wherein the amount of said human interferon is from about 102 to 108 I.U.
14. The composition of claim 1, wherein the amount of antiviral surface active agent is from about 0.1% to 20%
by weight of said composition.
by weight of said composition.
15. A therapeutic composition for the treatment of herpes simplex viral infections in humans by topical administration of an effective amount of the composition to the affected area, wherein the composition comprises an effective amount of human interferon, an effective amount of a suitable antiviral surface active agent, and a physiologically acceptable carrier.
16. The composition of claim 15 wherein the amount of antiviral surface active agent is about 1% to 5%.
- Page 2 of Claims -
- Page 2 of Claims -
17. The composition of claim 15 wherein the antiviral surface active agent is nonionic.
18. The composition of claim 17 wherein the nonionic surface active agent has at least one ether or amide linkage.
19. The composition of claim 17 wherein the nonionic surface active agent is nonylphenoxy-polyethoxy ethanol.
20. The composition of claim 17 wherein the nonionic surface active agent is p-diisobutylphenoxy-polyethoxy ethanol.
21. The composition of claim 17 wherein the nonionic surface active agent is polyoxyethylene (10) oleyl ether.
22. The composition of claim 17 wherein the human interferon is leukocyte interferon.
23. The composition of claim 15 wherein the amount of human interferon is about 104 to 106 I.U.
24. The composition of claim 15 wherein the carrier includes water, ethanol, polyethylene glycol, mineral oil, petrolatum, or propylene glycol.
25. The therapeutic composition of claim 14 wherein said carrier is a pharmaceutically acceptable carrier.
26. The therapeutic composition of claim 14 wherein said carrier is a cosmetically acceptable carrier.
27. The composition of claim 14, wherein the amount of said human interferon is from about 102 to 108 I.U.
- Page 3 of Claims -
- Page 3 of Claims -
28. The composition of claim 15, wherein the amount of said antiviral surface active agent is from about 0.1% to 20%
of the weight of said composition.
of the weight of said composition.
29. A therapeutic composition as in claim 15, wherein the composition is topically administered to an affected area prior to the appearance of a lesion due to herpes simplex infection.
30. A therapeutic composition as in claim 15, wherein the composition is applied to the genital area of a human.
31. A therapeutic composition as in claim 15, wherein the composition is applied in a foam, spray, tampon, or vaginal suppository.
32. A therapeutic composition as in claim 15, wherein the composition is applied to the topical area every 2-4 hours.
- Page 4 of Claims -
- Page 4 of Claims -
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31103581A | 1981-10-13 | 1981-10-13 | |
| US311,035 | 1981-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1190148A true CA1190148A (en) | 1985-07-09 |
Family
ID=23205109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000413238A Expired CA1190148A (en) | 1981-10-13 | 1982-10-12 | Interferon-containing compositions |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5877824A (en) |
| CA (1) | CA1190148A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP132A (en) * | 1990-02-01 | 1991-05-19 | Kenya Medical Res Institute | Improved formulation of low-dose interferon alpha. |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080032A3 (en) * | 1981-11-20 | 1985-11-13 | Enzo Biochem, Inc. | Pharmaceutical preparation for treating herpetic lesions |
| DE3436638C2 (en) * | 1984-10-05 | 1992-10-08 | Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim | Use of preparations containing interferon-gamma (IFN-gamma) for the treatment of rheumatic diseases |
| JPS61277633A (en) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | Interferon composition |
| JPS62185030A (en) * | 1986-02-07 | 1987-08-13 | Toray Ind Inc | Interferon pharmaceutical for nasotracheal administration |
| CA1294215C (en) * | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1321347C (en) * | 1986-11-10 | 1993-08-17 | David C. Munch | Human leukocyte interferon composition and skin treatment |
| DE3731255A1 (en) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilization of therapeutically active proteins in pharmaceutical preparations |
| JPH0285443U (en) * | 1988-12-22 | 1990-07-04 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4184917A (en) * | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
| JPS5283936A (en) * | 1976-01-01 | 1977-07-13 | Ortho Pharma Corp | Single herpes virus inactivating acent |
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
| ZA796175B (en) * | 1978-11-24 | 1980-11-26 | Hoffmann La Roche | Purified proteins and process therefor |
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| MW2880A1 (en) * | 1979-07-31 | 1981-12-09 | Hoffmann La Roche | Homogeneous fibroblast interferon and method for manufacture thereof |
-
1982
- 1982-10-12 CA CA000413238A patent/CA1190148A/en not_active Expired
- 1982-10-13 JP JP57180547A patent/JPS5877824A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP132A (en) * | 1990-02-01 | 1991-05-19 | Kenya Medical Res Institute | Improved formulation of low-dose interferon alpha. |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6365050B2 (en) | 1988-12-14 |
| JPS5877824A (en) | 1983-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0077063B1 (en) | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis | |
| US4507281A (en) | Interferon-containing compositions | |
| US4285934A (en) | Treatment for herpes virus | |
| US4309989A (en) | Topical application of medication by ultrasound with coupling agent | |
| US4822605A (en) | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like | |
| US4381296A (en) | Treatment for herpes virus | |
| US20030072814A1 (en) | Topical pharmaceutical composition for the treatment of warts | |
| GB1577551A (en) | Medication for topical application by ultrasound | |
| AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| US4957734A (en) | Treatment of certain skin malignancies and pre-malignant skin lesions, herpes zoster and psoriasis | |
| CA1190148A (en) | Interferon-containing compositions | |
| BAKER et al. | Topical podofilox for the treatment of condylomata acuminata in women | |
| US4049798A (en) | Method for the treatment of Herpes Simplex | |
| US5182104A (en) | Topical virucidal composition for treatment of mucocutaneous tissue | |
| US4427684A (en) | Treatment and prevention of infection with herpes simplex and related viruses | |
| EP0502048B1 (en) | Use of caffeine in the treatment of herpes simplex virus infections | |
| Lozada-Nur et al. | Retrospective findings of the clinical benefits of podophyllum resin 25% sol on hairy leukoplakia: Clinical results in nine patients | |
| Rudy | Imiquimod (Aldara): modifying the immune response | |
| JPS58103324A (en) | Interferon composition and use for herpes infection treatment | |
| EP0105448B1 (en) | The use of undecylenic acid for the manufacture of a composition for the treatment of herpes labialis | |
| US20040101571A1 (en) | Use of hydrogen peroxide for the treatment of warts | |
| Nelson et al. | Clinical aspects of cutaneous leishmaniasis acquired in Texas | |
| US5977176A (en) | Compositions for the treatment of warts and herpes | |
| WO1998017288A1 (en) | Lithium containing medicament for combatting papilloma virus infections | |
| Nikkels et al. | Current treatments of muco-cutaneous herpes simplex virus infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |